(Q30378973)

21 June 2017

title

Oncotyrol--Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research. (English)

1 reference

21 June 2017

author

Petra Schnell-Inderst

4

object named as

Petra Schnell-Inderst

0 references

Theresa Hunger

object named as

Theresa Hunger

6

0 references

Uwe Siebert

object named as

Uwe Siebert

1

0 references

author name string

Beate Jahn

2

1 reference

21 June 2017

Ursula Rochau

3

1 reference

21 June 2017

Agnes Kisser

5

1 reference

21 June 2017

Gaby Sroczynski

7

1 reference

21 June 2017

Nikolai Mühlberger

8

1 reference

21 June 2017

Wolfgang Willenbacher

9

1 reference

21 June 2017

Simon Schnaiter

10

1 reference

21 June 2017

Gottfried Endel

11

1 reference

21 June 2017

Lukas Huber

12

1 reference

21 June 2017

Guenther Gastl

13

1 reference

21 June 2017

Oncotyrol HTA & Outcomes Research Working Group

14

1 reference

21 June 2017

publication date

28 July 2015

1 reference

Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen

21 June 2017

published in

1 reference

21 June 2017

volume

109

1 reference

21 June 2017

issue

4-5

1 reference

21 June 2017

page(s)

330-340

1 reference

Genomic and personalized medicine: foundations and applications

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

What is personalized medicine: sharpening a vague term based on a systematic literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Concepts of 'personalization' in personalized medicine: implications for economic evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Systematic assessment of decision-analytic models for chronic myeloid leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Medical decision analysis for first-line therapy of chronic myeloid leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of Screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Methods, procedures, and contextual characteristics of health technology assessment and health policy decision making: comparison of health technology assessment agencies in Germany, United Kingdom, France, and Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Are survival rates for Tyrol published in the Eurocare studies biased?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Breast cancer incidence and mortality in Tyrol/Austria after fifteen years of opportunistic mammography screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Introduction of organised mammography screening in Tyrol: results of a one-year pilot phase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Introduction of organised mammography screening in Tyrol: results following first year of complete rollout

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Do women with cancer have better survival as compared to men after adjusting for staging distribution?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Patient-reported urinary incontinence and erectile dysfunction following radical prostatectomy: results from the European Prostate Centre Innsbruck.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.ZEFQ.2015.06.012

10.1016/J.ZEFQ.2015.06.012

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference